Principal Financial Group Inc. Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Principal Financial Group Inc. cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 13.9% during the 4th quarter, HoldingsChannel reports. The institutional investor owned 584,952 shares of the medical device company’s stock after selling 94,215 shares during the quarter. Principal Financial Group Inc.’s holdings in DexCom were worth $45,492,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of DXCM. Principal Securities Inc. increased its stake in DexCom by 3.4% in the 4th quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock worth $316,000 after acquiring an additional 135 shares during the last quarter. Crossmark Global Holdings Inc. increased its position in shares of DexCom by 1.0% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 18,778 shares of the medical device company’s stock valued at $1,259,000 after purchasing an additional 182 shares during the last quarter. GPS Wealth Strategies Group LLC increased its position in shares of DexCom by 13.2% during the 4th quarter. GPS Wealth Strategies Group LLC now owns 1,587 shares of the medical device company’s stock valued at $123,000 after purchasing an additional 185 shares during the last quarter. Peterson Wealth Services increased its position in shares of DexCom by 7.1% during the 4th quarter. Peterson Wealth Services now owns 3,030 shares of the medical device company’s stock valued at $236,000 after purchasing an additional 201 shares during the last quarter. Finally, Magnolia Capital Advisors LLC increased its position in shares of DexCom by 2.6% during the 4th quarter. Magnolia Capital Advisors LLC now owns 8,198 shares of the medical device company’s stock valued at $638,000 after purchasing an additional 210 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DXCM has been the topic of several analyst reports. Leerink Partners cut their target price on DexCom from $90.00 to $87.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Morgan Stanley boosted their target price on DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Wells Fargo & Company boosted their target price on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Four research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $99.06.

DexCom Price Performance

Shares of DXCM stock opened at $89.34 on Friday. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a market capitalization of $34.90 billion, a price-to-earnings ratio of 62.48, a P/E/G ratio of 2.33 and a beta of 1.14. The stock has a fifty day simple moving average of $83.06 and a two-hundred day simple moving average of $75.85. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM) last issued its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts predict that DexCom, Inc. will post 2.02 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares of the company’s stock, valued at approximately $7,259,244.66. The trade was a 2.44 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total value of $228,920.94. Following the completion of the transaction, the chief operating officer now directly owns 268,644 shares of the company’s stock, valued at approximately $23,347,850.04. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by company insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.